RTP Wrapup 10/30
A test that assesses Tysabri's risk of causing potentially deadly side effects could boost demand of the multiple sclerosis drug, GlaxoSmithKline is not ready to talk about efforts to develop a successor to best selling asthma medicine Advair and RTI International researchers will try to make biomass "oil."
Testing Tysabri's risks
The scientist who was instrumental in developing Tysabri has come up with a test to identify patients at risk of getting a potentially deadly brain infection known as progressive multifocal leukoencephalopathy, or PML.
Tags: Tysabri, rtp, IPO, biofuels, asthma 0 Comments